Short answer
Jade Biosciences, Inc. (JBIO) filed an 8-K current report with the SEC on June 4, 2026 reporting Item 8.01 (Other Events). $150.0M common-stock offering: 10.0M shares priced at $15.00 each.
Jade Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- $150.0M common-stock offering: 10.0M shares priced at $15.00 each
- Net proceeds approximately $140.3M after discounts and expenses, strengthening funding capacity
- 30-day option for 1.5M additional shares, potentially increasing proceeds to approximately $161.5M
- Underwriters purchase shares at $14.10, implying $0.90 per-share underwriting discount
- Expected June 5, 2026 closing remains subject to customary conditions; dilution risk for existing shareholders
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Jade Biosciences, Inc. 8-K filings
Get the next JBIO 8-K as it lands
Follow JBIO for push alerts, or ask the research agent what this filing means.